-
Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA) has approved a supplementary Biologic License Application (sBLA) for its biosimilar Hanbeitai (bevacizumab). The approval expands the indications for which Hanbeitai can be used, now including cervical cancer, epithelial ovarian cancer, fallopian tube cancer, and…
-
Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline
•
China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion of a Series A + financing round for its subsidiary Hui Sheng Bio – pharmaceutical Co., Ltd. The funding round was led by Jilin Baixing Bairong Investment Center, with additional contributions from Jilin Province Private…
-
HutchMed Completes Enrollment for Phase III ESLIM-01 Study of Sovleplenib in ITP
•
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment in the ESLIM – 01 study, a pivotal Phase III trial assessing the efficacy and safety of sovleplenib in treating adult patients with primary immune thrombocytopenia (ITP) in China. This marks a significant milestone in…
-
RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer
•
China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase II study of its antibody – drug conjugate (ADC) candidate RC48 (disitamab vedotin). The study will assess the efficacy and safety of RC48…
-
Apeloa and Simcere Partner for CDMO Services and R&D Collaboration
•
China – based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced a partnership agreement with compatriot firm Simcere Pharmaceutical Group (HKG: 2096). The collaboration aims to enhance the research and development (R&D) and manufacturing capabilities of both companies through strategic alignment. Details of the…
-
Sino Biopharmaceutical’s CTTQ Partners with ProteLight for Antibacterial Peptide PL-5
•
China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ) has entered into an exclusive commercial cooperation agreement with compatriot firm Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. Under the terms of the agreement, CTTQ will be responsible for…
-
Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds
•
Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully raised a total of RMB 150 million (USD 21.73 million) across its Series A+, B, and B+ financing rounds. The funding rounds were led by ESCO Lifesciences Group, Luxin Venture Capital, and Qiming Venture Partners,…
-
Everest Medicines Outlines Strategic Plans for Expansion and Growth
•
China – based biopharmaceutical company Everest Medicines (HKG: 1952) has announced its strategic plans for the next two years and beyond as it progresses toward becoming a fully – integrated biopharmaceutical company. The company aims to develop capabilities across the full biotechnology value chain, including in – house discovery, in…
